Corcept Therapeutics Incorporated
CORT
Classement en actions
#1759
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Prix de l'action
$112.72
Dernière synchronisation: 2026-10-19
Capitalisation boursière
$12.18B
Changement (1 jour)
2.32%
Changement (1 an)
43.41%
Pays
US
Échange Corcept Therapeutics Incorporated (CORT)
Catégorie
Healthcare
Bénéfices pour Corcept Therapeutics Incorporated (CORT)
Bénéfices en Jun 2026 TTM : $26.37M
Selon les derniers rapports financiers de Corcept Therapeutics Incorporated, les bénéfices actuels de l'entreprise sont de $26.37M. En 2023, l'entreprise a réalisé un bénéfice de $124.56M, une augmentation par rapport à celui de 2022 qui était de $116.19M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Corcept Therapeutics Incorporated de 2001 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $26.37M | -83.67% |
| 2024 | $161.49M | 29.65% |
| 2023 | $124.56M | 7.20% |
| 2022 | $116.19M | -7.05% |
| 2021 | $125.01M | -5.01% |
| 2020 | $131.60M | 12.79% |
| 2019 | $116.68M | 26.61% |
| 2018 | $92.15M | 74.51% |
| 2017 | $52.81M | 548.72% |
| 2016 | $8.14M | -227.03% |
| 2015 | $-6.41M | -79.58% |
| 2014 | $-31.38M | -31.79% |
| 2013 | $-46.01M | 20.93% |
| 2012 | $-38.05M | 17.60% |
| 2011 | $-32.35M | 24.60% |
| 2010 | $-25.97M | 28.76% |
| 2009 | $-20.17M | 0.52% |
| 2008 | $-20.06M | 73.34% |
| 2007 | $-11.57M | -53.47% |
| 2006 | $-24.87M | 23.79% |
| 2005 | $-20.09M | -99.87% |
| 2004 | $-15.53B | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $1.35B | 5,019.14% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $1.21B | 4,470.06% |
HK
|
